Regeneron Announces Failure in Late-Stage Trial of Libtayo Combination Therapy
Regeneron (REGN) reported that its late-stage trial evaluating a combination therapy involving its anti-PD-1 immunotherapy, Libtayo, failed to meet its primary endpoint. The Phase 3 study compared the treatment against Merck's Keytruda (pembrolizumab). This outcome could impact Regeneron’s oncology pipeline and investor sentiment.
Topics: cancer_treatment immunotherapy pharma